We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $352M
1-Year Est. Return 220.14%
This Fund
S&P 500
This Quarter Est. Return
+57.34%
1 Year Est. Return
+220.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$507M
AUM Growth
+$179M
Cap. Flow
+$2M
Cap. Flow %
0.39%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$5.19M

Top Sells

Rank Stock Value
1
CAMP icon
CAMP4 Therapeutics
CAMP
+$3.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBIO
1
Zenas BioPharma
ZBIO
$2.04B
$142M 28.08%
3,919,159
+157,800
+4% +$5.19M
IMNM icon
2
Immunome
IMNM
$2.63B
$102M 20.21%
4,768,583
– –
SION
3
Sionna Therapeutics
SION
$2.06B
$102M 20.12%
2,478,030
– –
UPB
4
Upstream Bio Inc
UPB
$352M
$66.8M 13.18%
2,459,703
– –
CMPX icon
5
Compass Therapeutics
CMPX
$367M
$41.8M 8.25%
7,788,150
– –
BBOT
6
BridgeBio Oncology
BBOT
$690M
$32.9M 6.49%
2,626,946
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$181M
$18.6M 3.67%
3,035,825
-749,977
-20% -$3.19M

Similar funds

HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
FFO
Fiduciary Family Office Boca Raton, Florida $351M AUM 22.19% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Enavate Sciences's Q4 2025 Portfolio in Review

As of Q4 2025, Enavate Sciences held 7 positions worth $507M, up 55% from $328M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2025: portfolio turnover was 0%. Enavate Sciences opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences added most to Zenas BioPharma in Q4 2025, an estimated $5.19M increase.
  • Enavate Sciences's biggest Q4 2025 reduction was CAMP4 Therapeutics, cutting an estimated $3.19M.
  • Enavate Sciences's ten largest holdings make up 100% of its $507M portfolio in Q4 2025.
  • Enavate Sciences opened 0 new positions and closed 0 in Q4 2025.
  • Enavate Sciences's portfolio value rose 55% quarter-over-quarter to $507M.

Based on Enavate Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.